

Customer No.: 20462
Confirmation No.: 5432

Attorney Docket No. PU60560

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Brook, et al. Date: July 8, 2009
Serial No.: 10/576.411 Group Art Unit No.: 1626
Filed: April 20, 2006 Examiner: F. Powers
For: 2-(3,4-Dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-
hydrazono]-5-methyl-2,4-dihydropyrozol-3-one choline


Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This information disclosure statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), i.e., **after** three months of the filing date of the subject application or after the mailing date of the first Office Action on the merits, whichever event occurred last but **before** the mailing date of either a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090